Share

June 09, 2020; 94 (23) Article

Fractures in the prodromal period of Parkinson disease

Alejandra Camacho-Soto, Anat Gross, Susan Searles Nielsen, Anna N. Miller, Mark N. Warden, Amber Salter, Brad A. Racette
First published April 28, 2020, DOI: https://doi.org/10.1212/WNL.0000000000009452
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
96

Share

Article Information

vol. 94 no. 23 e2448-e2456
DOI: 
https://doi.org/10.1212/WNL.0000000000009452
PubMed: 
32345729
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received July 6, 2019
  • Accepted in final form December 2, 2019
  • First Published April 28, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Alejandra Camacho-Soto, MD,
    2. Anat Gross, MS,
    3. Susan Searles Nielsen, PhD,
    4. Anna N. Miller, MD,
    5. Mark N. Warden, MS,
    6. Amber Salter, PhD and
    7. Brad A. Racette, MD
  1. Alejandra Camacho-Soto, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Funding source: Rehabilitation Medicine Scientist Training Program (RMSTP) Fellowship NIH K12 Grant number: 5K12 HD001097-19 Role: PI/Fellow Years: 2015-2017

    Research Support, Academic Entities:

    1. Funding source: Washington University School of Medicine Faculty Diversity Scholar Award Role: PI Years: 2018-2020

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Anat Gross, MS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Susan Searles Nielsen, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) International Journal of Molecular Epidemiology and Genetics, Associate Board Member, 2012-present.

    Patents:

    1. (1) Provisional patent application submitted for methods of lowering the risk for developing a neurodegenerative disease.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH-NIEHS, R01ES025991 and R01ES025991-O2S1, Co- Investigator, 2015-present, (2) NIH-NIEHS, R01ES021488, Data Analyst, 2014-present, (3) NIH-NIEHS, R21ES024120, 2014- 2016, (4) NIH-NIEHS, R01ES017462, Data Analyst, 2013-2015, (5) NIH-NIEHS, P42ES004696, Data Analyst, 2010-2014, (6) NIH-NIEHS, R01 ES026891, Co-Investigator, (7) NIH-NIEHS, K01ES028295, 2018-present, PI.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Michael J. Fox Foundation, (2) American Parkinson Disease Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Anna N. Miller, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Orthopaedic Trauma associate editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Bonesupport

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Mark N. Warden, MS,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH K24ES017765, Analyst.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Michael J. Fox Foundation, (2) American Parkinson Disease Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Amber Salter, PhD and
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Circulation:Cardiovascular Imaging, 2018-2019

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Brad A. Racette, MD
    8. Scientific Advisory Boards:

    1. National Advisory Environmental Health Sciences Council

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. All the below are multi-center clinical trials: Allergan Teva Pharmaceuticals Civitas Therapeutics Ipsen US World Meds

    Research Support, Government Entities:

    1. NIH R01ES025991 (PI-Racette) 7/1/2015 – 6/30/2020 “Motor and Cognitive Health Outcomes in a Mn-Exposed African Community” K24 NS060825 (PI-Racette) 4/1/2009 – 6/30/20 “Epidemiology and Biomarkers of Parkinsonism in Welders” R01ES025991-02S1 (Racette) 05/01/2017 – 10/31/2020 “Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER)” R01ES026891 (PI-Racette) 9/1/2017 - 8/31/2022 “Manganese-Induced Neurotoxic Effects Research in South Africa (MINERS)” R01ES029524 (PI- Criswell) 04/01/19 – 03/31/24 Novel PET Markers of Cognitive Impairment in Manganese Neurotoxicity R01ES030937-S1(PI-Tjalkens) 08/01/2019-07/31/22 Encephalitic viral infection and susceptibility to dopaminergic neurotoxins ROH01166 (PI-Checkoway) 07/01/2019-06/30/23 Manganese-Related Motor and Cognitive Toxicity Among Professional Welders

    Research Support, Academic Entities:

    1. Hope Center for Neurologic Disorders (PI-Racette) 1/1/2019-12/31/2021 “Identification of Repurposed Prescription Medications as Neuroprotective

    Research Support, Foundations and Societies:

    1. Michael J. Fox Foundation American Parkinson Disease Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Johnson and Bell, retained expert, 2019

  1. From the Departments of Neurology (A.C.-S., A.G., S.S.N., M.N.W., B.A.R.) and Orthopedic Surgery (A.N.M.) and Division of Biostatistics (A.S.), Washington University School of Medicine, St. Louis, MO; and School of Public Health, Faculty of Health Sciences (B.A.R.), University of the Witwatersrand, Johannesburg, South Africa.
  1. Correspondence
    Dr. Racette racetteb{at}neuro.wustl.edu
View Full Text

Article usage

Article usage: April 2020 to March 2021

AbstractFullPdfSource
Apr 202019806Highwire
May 2020342016Highwire
Jun 20207915635Highwire
Jul 2020167129Highwire
Aug 20206064Highwire
Sep 202022873Highwire
Oct 20209196Highwire
Nov 20207345Highwire
Dec 20205142Highwire
Jan 20214544Highwire
Feb 20212863Highwire
Mar 20215433Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Related Articles

Topics Discussed

Alert Me